Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies1000
Freenome
Freenome develops non-invasive disease screening products for early detection and treatment of cancer and other diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Oncimmune
Oncimmune is a company that specializes in early cancer detection.
Sector
Subsector
Location
total rounds
total raised
Capsulomics
Capsulomics detects esophageal cancer and Barrett's esophagus early.
Sector
Subsector
Location
total rounds
total raised
Rarecells
Rarecells, Inc. develops non-invasive early cancer detection tests based on the ISET® platform technology.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds2
Number of Funding Rounds
Money Raised
Their latest funding was raised on 03.04.2023. Their latest investor Novalis LifeSciences. Their latest round Series A
Novalis LifeSciences
Novalis Lifesciences is a global venture capital firm that invests in breakthrough technologies in Life Science.
Sector
Subsector
Location
count Of Investments
Co-Investors
Investors9
Number of lead investors
Number of investors
Novalis LifeSciences
Novalis Lifesciences is a global venture capital firm that invests in breakthrough technologies in Life Science.
Sector
Subsector
Location
count Of Investments
iSELECT FUND
iSelect Fund invests in sustainable food, agriculture, and healthcare startups.
Sector
Subsector
Location
total rounds
count Of Investments
count Of Exists
Hatteras Venture Partners
Hatteras Venture Partners invests in transformative companies in healthcare and related fields.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
People
Founders2
Joseph Sedlak
Joseph is the Co-Founder and Chief Scientific Officer of Mercy BioAnalytics. Joseph graduated summa cum laude from the University of Michigan with a degree in biomedical engineering and entered the M.D./Ph.D. program at Harvard Medical School to pursue his mission to improve the lives of those with cancer. Since arriving at Harvard, Joseph focused on reducing the mortality and morbidity of cancer by seeking clinical opportunities to help care for cancer patients and studying in several research labs across Harvard and MIT. These research experiences included modeling the evolution of cancer resistance to small molecules, studying immunotherapy resistance, and biomarker assay development. Informed by his experiences working with patients and the body of ongoing cancer research, Joseph critically assessed early detection as the largest unmet need in the field of oncology. The majority of early-stage, localized cancers can be cured by surgery alone. However, as cancer progresses and distant metastases have developed, surgery is rarely curative. After gaining insight into the challenges of early cancer detection and seeing the need for detecting cancers earlier go unmet, Joseph dedicated his efforts to improving cancer screening by co-founding Mercy BioAnalytics. Joseph is now on an authorized leave of absence from Harvard Medical School and plans to return to his fifth year in the M.D./Ph.D. program after seeing Mercy’s technology reach patients in prospective randomized clinical trials.
current job
organization founded
Joseph Sedlak
Paul Blavin
Paul is the co-founder and CEO of Mercy BioAnalytics. He began his career in 1986 as an investment banker with Citibank and Donaldson, Lufkin & Jenrette. He then served as the President of First Mercury Financial Corporation, a publicly-traded insurance company. He also co-founded and managed a private investment partnership – PWB Value Partners, L.P. – which began with three investors and $3.2 million under management. Over 14 years, the business grew to more than 80 investors and approximately $2.0 billion, consistently outperforming the S&P 500 Index, net of all fees and expenses. Paul was born and raised in Southfield, Michigan just outside of Detroit. He graduated Phi Beta Kappa with High Distinction with a BBA in Accounting from the University of Michigan and earned an MBA at Harvard Business School.
current job
organization founded
Paul Blavin
Employee Profiles3
Activity
Recent News3
The graph reveals the ratio (%) of positive news articles in a chosen time range